Cellceutix Cancer Drug Trumps Competitors
Kevetrin™ Stands Out in Its Mechanism of Action by Activating Both Transcription-Dependent and Transcription-Independent Pathways to Promote Apoptosis in a Non-Genotoxic Manner and Targets Both Mutated and Wild Type p53
BEVERLY, MA–(Marketwire – Apr 25, 2011) – Cellceutix Corporation (OTCQB: CTIX) (OTCBB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, announced that at the 102nd annual American Association for Cancer Research (AACR) meeting held in Orlando, FL, April 2nd to 6th, four posters described new compounds that directly affected p53 function. p53, also known as the “Guardian Angel of the human genome” due to its crucial role in controlling cell mutations, is a tumor suppressor protein that is encoded by the TP53 gene in humans and has been widely regarded as possibly holding a key to the future of cancer therapies. Aside from Cellceutix’s compound, Kevetrin™, none of the other three compounds demonstrated success against a broad spectrum of cancers.
Compound A and Compound B, reported by Wang, et al, (Ascenta Therapeutics, Abstract #LB-204) and MI-63 reported by Scott et al, (Abstract #4507) showed efficacy in tumors limited to wild type p53. Pernaza et al, (Abstract #3242) reported that compound E12/DP13-117 was also “expected to work” on tumors containing only wild type p53. These novel compounds only affect tumors with wild type p53. Kevetrin™ affects both wild type and mutant p53 by modulating E3 ligase processivity, a unique mechanism of action which distinguishes it from the other three drugs.
CEO of Cellceutix, Leo Ehrlich, commented, “It is often times difficult to explain the magnitude of the potential of Kevetrin™. Compounds that affect only wild type p53 address only a fraction of the tumors that Kevetrin™ has the potential to treat. This past June, an emerging biopharmaceutical company announced they had signed an agreement with a major pharmaceutical company covering early-stage agents being investigated for their potential to restore tumor cell apoptosis related to p53. Per the announcement, milestone payments could reach approximately $400 million in addition to royalties from sales. It seems that that compound is also at an earlier stage of development than ours. Considering that Kevetrin could potentially address double the number of cancer patients with either mutated or wild type p53, I would expect Kevetrin™ to have a value significantly greater than that.”
Cellceutix Corporation is presently a preclinical drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for cancers; KM-133, for the treatment of psoriasis; and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
Kevetrin, KM-133, and KM-391 have not been studied in humans at this time. The Company’s positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Cellceutix Corporation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.